Modak S - Search Results

1

5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.

Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Kushner BH, et al. Among authors: modak s. Bone Marrow Transplant. 2013 May;48(5):642-5. doi: 10.1038/bmt.2012.202. Epub 2012 Oct 22. Bone Marrow Transplant. 2013. PMID: 23085829

2

Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.

Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Modak S, et al. Cancer Res. 2001 May 15;61(10):4048-54. Cancer Res. 2001. PMID: 11358824

3

Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification.

Kushner BH, LaQuaglia MP, Modak S, Cheung NK. Kushner BH, et al. Among authors: modak s. Med Pediatr Oncol. 2003 Jul;41(1):80-2. doi: 10.1002/mpo.10287. Med Pediatr Oncol. 2003. PMID: 12764755 No abstract available.

4

Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Kushner BH, et al. Among authors: modak s. Med Pediatr Oncol. 2003 Dec;41(6):508-15. doi: 10.1002/mpo.10273. Med Pediatr Oncol. 2003. PMID: 14595707

5

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.

Kushner BH, Kramer K, Modak S, Cheung NK. Kushner BH, et al. Among authors: modak s. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):84-7. doi: 10.1158/1078-0432.ccr-1147-3. Clin Cancer Res. 2004. PMID: 14734455

6

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK. Kushner BH, et al. Among authors: modak s. J Clin Oncol. 2004 Dec 15;22(24):4888-92. doi: 10.1200/JCO.2004.02.101. J Clin Oncol. 2004. PMID: 15611504 Clinical Trial.

7

Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

Kushner BH, Kramer K, Modak S, Cheung NK. Kushner BH, et al. Among authors: modak s. Cancer. 2005 Feb 15;103(4):858-62. doi: 10.1002/cncr.20846. Cancer. 2005. PMID: 15637685 Free article.

8

Long-term complications in survivors of advanced stage neuroblastoma.

Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA. Laverdière C, et al. Among authors: modak s. Pediatr Blood Cancer. 2005 Sep;45(3):324-32. doi: 10.1002/pbc.20331. Pediatr Blood Cancer. 2005. PMID: 15714447

9

Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Kushner BH, et al. Among authors: modak s. Pediatr Blood Cancer. 2006 Mar;46(3):278-84. doi: 10.1002/pbc.20564. Pediatr Blood Cancer. 2006. PMID: 16124002

10

Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.

Kushner BH, Kramer K, Modak S, Kernan NA, Reich LM, Danis K, Cheung NK. Kushner BH, et al. Among authors: modak s. Bone Marrow Transplant. 2006 Feb;37(3):271-6. doi: 10.1038/sj.bmt.1705253. Bone Marrow Transplant. 2006. PMID: 16400336 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters